GoAI
Get started
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc.

TMCI

NASDAQHealthcareMedical - Devices

Open in GoAI

Regular session

$4.29

−$0.05 · -1.15%

Aug 24, 2:49 PM ET

TMCI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

55

Fair Value

Momentum

58

Neutral

Sentiment

52

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
John T. Treace
Listed since
Apr 23, 2021
Employees
450

Market position

Day range

Current $4.29

52-week range

Current $4.29

Open
$4.39
Previous close
$4.34
Volume
194.3K
0.3× average
Average volume
645.16K
Average daily volume
Market cap
278.31M USD
Beta
1.4
Market reference 1
50-day average
$4.3446
-1.26% below average
200-day average
$2.8943
+48.22% above average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-0.02
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends93%48%4%-41%Gross margin, FY2021: 82.11%Gross margin, FY2022: 80.60%Gross margin, FY2023: 81.20%Gross margin, FY2024: 80.37%Gross margin, FY2025: 79.81%Operating margin, FY2021: -17.49%Operating margin, FY2022: -24.57%Operating margin, FY2023: -27.48%Operating margin, FY2024: -26.60%Operating margin, FY2025: -25.46%Net margin, FY2021: -21.77%Net margin, FY2022: -30.19%Net margin, FY2023: -26.47%Net margin, FY2024: -26.63%Net margin, FY2025: -27.74%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 82.11%. Gross margin FY2022 80.60%. Gross margin FY2023 81.20%. Gross margin FY2024 80.37%. Gross margin FY2025 79.81%. Operating margin FY2021 -17.49%. Operating margin FY2022 -24.57%. Operating margin FY2023 -27.48%. Operating margin FY2024 -26.60%. Operating margin FY2025 -25.46%. Net margin FY2021 -21.77%. Net margin FY2022 -30.19%. Net margin FY2023 -26.47%. Net margin FY2024 -26.63%. Net margin FY2025 -27.74%.

Income trends

Revenue

212.69M USD+1.59%

Operating income

−54.15M USD+2.75%

Net income

−59M USD-5.85%
Income trends across reported periods239.86M USD131.18M USD22.51M USD−86.17M USDRevenue, FY2021: 94.42M USDRevenue, FY2022: 141.84M USDRevenue, FY2023: 187.12M USDRevenue, FY2024: 209.36M USDRevenue, FY2025: 212.69M USDOperating income, FY2021: −16.51M USDOperating income, FY2022: −34.84M USDOperating income, FY2023: −51.43M USDOperating income, FY2024: −55.69M USDOperating income, FY2025: −54.15M USDNet income, FY2021: −20.55M USDNet income, FY2022: −42.82M USDNet income, FY2023: −49.53M USDNet income, FY2024: −55.74M USDNet income, FY2025: −59M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 94.42M USD. Revenue FY2022 141.84M USD. Revenue FY2023 187.12M USD. Revenue FY2024 209.36M USD. Revenue FY2025 212.69M USD. Operating income FY2021 −16.51M USD. Operating income FY2022 −34.84M USD. Operating income FY2023 −51.43M USD. Operating income FY2024 −55.69M USD. Operating income FY2025 −54.15M USD. Net income FY2021 −20.55M USD. Net income FY2022 −42.82M USD. Net income FY2023 −49.53M USD. Net income FY2024 −55.74M USD. Net income FY2025 −59M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue212.69M USD209.36M USD187.12M USD141.84M USD94.42M USD
Cost of goods sold42.94M USD41.09M USD35.18M USD27.52M USD16.89M USD
Gross profit169.75M USD168.26M USD151.94M USD114.32M USD77.53M USD
Research and development20.28M USD20.59M USD15.44M USD13.58M USD10.2M USD
Selling, general, and administrative203.62M USD203.36M USD187.93M USD137.57M USD83.84M USD
Operating expenses223.91M USD223.95M USD203.37M USD149.16M USD94.04M USD
Interest income2.78M USD4.88M USD6.73M USD1.31M USD18K USD
Interest expense5.32M USD5.26M USD5.17M USD4.4M USD4.06M USD
Depreciation and amortization10.5M USD8.42M USD5.35M USD2.13M USD685K USD
Operating income−54.15M USD−55.69M USD−51.43M USD−34.84M USD−16.51M USD
Net income−59M USD−55.74M USD−49.53M USD−42.82M USD−20.55M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+12.19%
11 comparable reports
Latest EPS result
-0.24
Estimate -0.3 · Beat by 19.46%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-0.12-0.24-0.35Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.01, estimate -0.04, surprise +75.00%, Beat. Q2 2025, reported May 8, 2025: actual -0.25, estimate -0.31, surprise +19.35%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.28, estimate -0.29, surprise +3.45%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.26, estimate -0.28, surprise +7.14%, Beat. Q1 2026, reported Feb 27, 2026: actual -0.12, estimate -0.152, surprise +21.00%, Beat. Q2 2026, reported May 8, 2026: actual -0.28, estimate -0.31, surprise +9.68%, Beat. Q3 2026, reported Aug 7, 2026: actual -0.24, estimate -0.298, surprise +19.46%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates71.46M61.39M51.33M41.27MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 68.71M USD, estimate 67.19M USD, surprise +2.26%, Beat. Q2 2025, reported May 8, 2025: actual 52.57M USD, estimate 49.52M USD, surprise +6.16%, Beat. Q3 2025, reported Aug 7, 2025: actual 47.39M USD, estimate 49.85M USD, surprise -4.95%, Miss. Q4 2025, reported Nov 6, 2025: actual 50.21M USD, estimate 61.76M USD, surprise -18.70%, Miss. Q1 2026, reported Feb 27, 2026: actual 62.52M USD, estimate 61.85M USD, surprise +1.08%, Beat. Q2 2026, reported May 8, 2026: actual 47.2M USD, estimate 45.96M USD, surprise +2.69%, Beat. Q3 2026, reported Aug 7, 2026: actual 45.38M USD, estimate 44.02M USD, surprise +3.08%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 47.71M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.60

100.47% upside
Past 12 months12-month forecast

Price history unavailable

High $16.00Average $8.60Low $3.00

Rating distribution

9 ratings
Strong buy00%
Buy222%
Hold667%
Sell111%
Strong sell00%

Recent analyst actions

8 institutions
Lake StreetmaintainBuy
Stephens & Co.maintainEqual Weight

TMCI news

seekingalpha.com

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Treace Medical Concepts Q2 Earnings Call Highlights

Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward…

Read source
zacks.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

Read source
globenewswire.com

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of…

Read source
prnewswire.com

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket…

Read source
globenewswire.com

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of…

Read source

TMCI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$443.27

+0.90%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.45

+0.22%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.21

+0.03%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$375.25

-0.94%

Sanofi logo

SNY

Sanofi

$45.6674

-0.40%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$827.24

-0.82%

ETFs holding TMCI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.24M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.47-0.20%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.48M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.65-0.77%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
989.34K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.495-0.98%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
742.81K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$196.56-0.80%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
656.33K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.04-0.20%
iShares Core S&P Total U.S. Stock Market ETF logoiShares Core S&P Total U.S. Stock Market ETFITOT
Market value
317.15K
Weight
0.00%
AUM
97.17B USD
Expense ratio
0.03%
Price / 1D
$167.58-0.23%
Schwab U.S. Broad Market ETF logoSchwab U.S. Broad Market ETFSCHB
Market value
237K
Weight
0.00%
AUM
44.6B USD
Expense ratio
0.03%
Price / 1D
$29.545-0.22%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
146.02K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$82.59-0.52%

Continue in GoAI

Research TMCI

research.disclaimer